Allergan plc recently announced it received U.S. FDA approval for its Restasis Multidose™ (Cyclosporine Ophthalmic Emulsion) 0.05% — a preservative-free, multi-dose bottle offering the same preservative-free formulation of Restasis since its launch in 2003.
Designed to help increase the eyes' natural ability to product tears, the Restasis Multidose reportedly allows healthcare providers to offer an additional option for patients who prefer their eye drops in a multi-dose bottle versus single-dose vials.
The product is reportedly designed with a patented unidirectional valve and air filter technology that eliminates the need for a preservative. The new multi-dose bottle also uses less plastic than a package of single-use vials and will be available for the same price.
Click here to read the full press release.